| scholarly article | Q13442814 |
| P2093 | author name string | M-C Wu | |
| S-H Zhang | |||
| W-M Cong | |||
| W-Q Wu | |||
| Z-H Xian | |||
| P2860 | cites work | Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients | Q46464385 |
| Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts | Q47854934 | ||
| Accuracy and precision in HER2/neu testing in breast cancer: are we there yet? | Q48021220 | ||
| Determination of the oncogenes p53 and C-erb B2 in the tumour cytosols of advanced hepatocellular carcinoma (HCC) and correlation to survival time. | Q52977312 | ||
| C-erb-B-2 oncoprotein and epidermal growth factor receptor in human hepatocellular carcinoma: an immunohistochemical study | Q72639491 | ||
| Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system | Q73181576 | ||
| Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors: a comparative study involving results from laboratories in 21 countries | Q74761182 | ||
| Treatment of hepatocellular carcinoma | Q77096102 | ||
| The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy | Q28191663 | ||
| Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer | Q33598660 | ||
| Biologic and therapeutic role of HER2 in cancer | Q34267775 | ||
| The prognostic molecular markers in hepatocellular carcinoma | Q34668320 | ||
| Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays | Q35396369 | ||
| Best Practice No 176: Updated recommendations for HER2 testing in the UK | Q35587451 | ||
| Use of tissue microarray for interlaboratory validation of HER2 immunocytochemical and FISH testing | Q35588100 | ||
| Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma | Q36622264 | ||
| Incidence, mechanism and prognostic value of activated AKT in pancreas cancer | Q36648105 | ||
| P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. | Q40550119 | ||
| Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fr | Q40568575 | ||
| Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents | Q40775553 | ||
| Epidermal growth factor receptor expression is a candidate target of the synergistic combination of trastuzumab and flavopiridol in breast cancer. | Q42163064 | ||
| Guidelines for HER2 testing in the UK. | Q43010802 | ||
| Progress in research of liver surgery in China. | Q43064716 | ||
| c-erbB-2 oncogene expression in hepatocellular carcinoma and cholangiocarcinoma | Q43526977 | ||
| HER-2/neu overexpression is rare in hepatocellular carcinoma and not predictive of anti-HER-2/neu regulation of cell growth and chemosensitivity | Q43921056 | ||
| C-erb B2 (Her2/neu) is neither overexpressed nor amplified in hepatic neoplasms | Q44174661 | ||
| Feasibility of using tissue microarrays for the assessment of HER-2 gene amplification by fluorescence in situ hybridization in breast carcinoma | Q46227456 | ||
| Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. | Q46246951 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | overexpression | Q61643320 |
| P304 | page(s) | 500-503 | |
| P577 | publication date | 2005-05-01 | |
| P1433 | published in | Journal of Clinical Pathology | Q6294965 |
| P1476 | title | Overexpression/amplification of HER-2/neu is uncommon in hepatocellular carcinoma | |
| P478 | volume | 58 |
| Q64129433 | Combined therapy of transcatheter hepatic arterial embolization with intratumoral dendritic cell infusion for hepatocellular carcinoma: clinical safety |
| Q36519010 | Dysregulation of growth factor signaling in human hepatocellular carcinoma. |
| Q28078111 | HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists |
| Q37639917 | Hepatitis B virus X upregulates HuR protein level to stabilize HER2 expression in hepatocellular carcinoma cells. |
| Q38073827 | Investigational therapies targeting the ErbB (EGFR, HER2, HER3, HER4) family in GI cancers |
| Q64279990 | Recognition of HER2 expression in hepatocellular carcinoma and its significance in postoperative tumor recurrence |
| Q58693837 | Silencing the expression of copine-III enhances the sensitivity of hepatocellular carcinoma cells to the molecular targeted agent sorafenib |
| Q42180761 | TOP2A amplification and overexpression in hepatocellular carcinoma tissues. |
| Q54942120 | The HER-2 as a Target Gene of Curcumin to Protect Hepatocytes Against the Arsenic-induced Carcinoma in Mice. |
| Q36395424 | The Predictive and Prognostic Significance of c-erb-B2, EGFR, PTEN, mTOR, PI3K, p27, and ERCC1 Expression in Hepatocellular Carcinoma |
| Q38959732 | The interrelationship between HER2 and CASP3/8 with apoptosis in different cancer cell lines. |
| Q80554209 | [Molecular pathogenesis of hepatocellular carcinoma: new therapeutic approaches and predictive pathology] |
| Q50091796 | [Nuclear Her2 expression in hepatocytes in liver disease]. |
Search more.